Month: February 2024

Nextech3D.ai Featured in Syndicated Broadcast Highlighting Launch of Next Era of GPT AI 3D Solutions

Written by Customer Service on February 20, 2024. Posted in Public Companies.

LOS ANGELES, Feb. 20, 2024 (GLOBE NEWSWIRE) — via IBN — Nextech3D.ai (CSE: NTAR) (OTCQX: NEXCF) (FSE: 1SS), a Generative AI-Powered 3D model supplier for Amazon, P&G, Kohls, Miele and others including major e-commerce platform integrations with Shopify, BigCommerce and WooCommerce, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio news release covers Nextech3D.ai’s recent announcement of the launch of the next era of GPT AI 3D product solutions leveraging proprietary algorithms. To hear the audio production, visit: https://www.nnw.fm/VFivh To read the original press release, visit: https://nnw.fm/H4iQF The initiative...

Carrum Health and The Oncology Institute Partner on Breast Cancer Treatment Model

Written by Customer Service on February 20, 2024. Posted in Public Companies.

Value-based care program offers Las Vegas patients access to high quality cancer care while reducing costs for employers SAN FRANCISCO and LAS VEGAS, Feb. 20, 2024 (GLOBE NEWSWIRE) — Today, The Oncology Institute (TOI), one of the largest value-based oncology practices in the country, announced its partnership with Carrum Health. This collaboration aims to provide high-quality, cost-effective breast cancer care to patients in TOI’s Las Vegas, Nevada market, with plans for further expansion into additional markets in the coming year. Through employers, Carrum Health will offer patients a comprehensive bundled package for breast cancer care, covering two years treatment, including chemotherapy, office visits, and symptom management through TOI. The partnership will focus on patients with non-metastatic breast cancer patients in Las...

Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers

Written by Customer Service on February 20, 2024. Posted in Public Companies.

WILMETTE, Ill., Feb. 20, 2024 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced it has received Human Research Ethics Committee (HREC) clearance in Australia to commence a Phase 1 dosimetry trial of its novel radiopharmaceutical MNPR-101-Zr. The MNPR-101-Zr Phase 1 dosimetry clinical trial will enroll patients with advanced cancers and will utilize positron emission tomography (PET) imaging to assess tumor uptake, normal organ biodistribution, and safety. MNPR-101-Zr is a zirconium-89 (imaging radioisotope) labeled version of MNPR-101, Monopar’s proprietary first-in-class humanized monoclonal antibody that is highly selective against the urokinase plasminogen activator receptor (uPAR). PET imaging...

Finning announces director resignation

Written by Customer Service on February 20, 2024. Posted in Public Companies.

VANCOUVER, British Columbia, Feb. 20, 2024 (GLOBE NEWSWIRE) — Finning International Inc. (TSX: FTT) (“Finning” or the “Company” or “we”, “our” or “us”) today announced that Christopher Patterson, a member of the company’s Board of Directors (Board), has decided to step down from the Board for personal reasons, effective February 16, 2024. “Chris has been a valuable member of the Board and we have appreciated his experience and thoughtful insights over the course of his 14-year tenure,” said Harold Kvisle, chair of Finning’s Board of Directors. Mr. Kvisle added, “On behalf of the Board, I would like to thank Chris for his service and longstanding commitment to Finning, and we wish him all the best in the future.” About FinningFinning International is the world’s largest Caterpillar dealer delivering unrivalled service to customers...

Xcel Brands Announces Participation in Noble Capital Markets C-Suite Interview Series

Written by Customer Service on February 20, 2024. Posted in Public Companies.

NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) — Xcel Brands, Inc. (NASDAQ: XELB), a media and consumer products company with expertise in livestream shopping and social commerce, announced their participation in Noble Capital Markets’ C-Suite Interview Series, presented by Channelchek. Xcel Brands CEO, Robert D’Loren, sat down with Noble Capital Markets Senior Research, Michael Kupinski, for this exclusive two-part series. Topics covered include:Part one, Xcel Brands CEO Robert D’Loren provides a corporate overview, discussing Xcel’s core business model, their brands, key revenue figures, current financial outlook, and their new e-commerce platform, ORME. Learn more on Xcel Brands here. Part two highlights the launch of ORME, a next generation short form video marketplace, which will become a game changer in the social influencer...

Banzai Gives Business Update Including End-of-Year 2023 ARR, Additional Executed LOI and End-of-Year 2024 ARR Target

Written by Customer Service on February 20, 2024. Posted in Mergers And Acquisitions.

ARR for December 2023 was $4.6 million Executed LOI to Acquire Mixed Analytics, a Data Analytics Solution Banzai Targets December 2024 ARR to be $8.1 – $10 millionSEATTLE, Feb. 20, 2024 (GLOBE NEWSWIRE) — Banzai International, Inc. (NASDAQ: BNZI) (“Banzai” or the “Company”), a leading marketing technology company that provides essential marketing and sales solutions, today announced a business update that includes December 2023 Annual Recurring Revenue (“ARR”), the execution of a non-binding letter of intent (the “LOI”) to acquire Mixed Analytics as well as the Company’s target December 2024 ARR. Banzai has estimated its December 2023 ARR at $4.6 million. Banzai selected ARR as a key performance metric next to GAAP measures, as it annualizes contracted recurring revenue components of term subscriptions and represents a...

Form 8.3 – [ LXi REIT PLC – 19 02 2024] – (CGWL)

Written by Customer Service on February 20, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree LXi REIT PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position held/dealing...

Recursion to Host Public L(earnings) Call on February 27

Written by Customer Service on February 20, 2024. Posted in Earnings Releases And Operating Results.

SALT LAKE CITY, Feb. 20, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its fourth quarter and full year 2023 financial results on Tuesday, February 27, 2024, following the close of the financial markets. Additionally, Recursion will host its first-ever L(earnings) Call on February 27, 2024 at 5:00 pm Eastern Time / 3:00 pm Mountain Time. A L(earnings) Call is Recursion’s take on interacting with a broad public audience around notable business developments and offering opportunities to ask questions. Recursion will broadcast the live stream from Recursion’s X (formerly Twitter), LinkedIn and YouTube accounts. This event is free, open to the public and encouraged, especially for...

Form 8.3 – [abrdn EUROPEAN LOGISTICS INCOME PLC – 19 02 2024] – (CGWL)

Written by Customer Service on February 20, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree abrdn EUROPEAN LOGISTICS INCOME PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date...

Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement

Written by Customer Service on February 20, 2024. Posted in Mergers And Acquisitions.

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) — Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today announced that at an extraordinary general meeting of shareholders (the “EGM”) held on February 19, 2024, the Company’s shareholders voted in favor of the proposal to approve and authorize the execution, delivery and performance by the Company of the previously announced Agreement and Plan of Merger, dated as of December 23, 2023 (the “Merger Agreement”), by and among the Company, AstraZeneca Treasury Limited, a private limited company incorporated under the laws of England and Wales (“Parent”), and...

Month: February 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals